Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with G / Glimepiride

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.
Sandoz glimepiride
CategoriesHypoglycemic Agents
Antiarrhythmic Agents
Immunosuppressive Agents
Anti-Arrhythmia Agents
ManufacturersSanofi aventis us llc
Accord healthcare inc
Carlsbad technology inc
Corepharma llc
Dr reddys laboratories ltd
Genpharm inc
Invagen pharmaceuticals inc
Mylan pharmaceuticals inc
Ranbaxy laboratories ltd
Teva pharmaceuticals usa inc
Vintage pharmaceuticals llc
Watson laboratories inc
Watson laboratories inc florida
PackagersAccord Healthcare
Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Cardinal Health
Carlsbad Technology Inc.
Cobalt Pharmaceuticals Inc.
Corepharma LLC
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
Heartland Repack Services LLC
Intas Pharmaceuticals Ltd.
International Laboratories Inc.
InvaGen Pharmaceuticals Inc.
Ivax Pharmaceuticals
Lake Erie Medical and Surgical Supply
Murfreesboro Pharmaceutical Nursing Supply
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Perrigo Co.
Pharmacy Service Center
Physicians Total Care Inc.
Prasco Labs
Prepak Systems Inc.
Ranbaxy Laboratories
Rebel Distributors Corp.
Resource Optimization and Innovation LLC
Sanofi-Aventis Inc.
Southwood Pharmaceuticals
Stat Scripts LLC
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Vangard Labs Inc.


For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.


Glimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.

mechanism of action

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.


Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.


Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear.


Completely (100%) absorbed following oral administration.

half life

Approximately 5 hours following single dose.

drug interactions

Cyclosporine: The sulfonylurea, glimepiride, may increase the effect of cyclosporine.

Gemfibrozil: Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone

Glucosamine: Possible hyperglycemia

Ketoconazole: Ketoconazole increases the effect of rosiglitazone

Rifampin: Rifampin may decrease the effect of sulfonylurea, glimepiride.

Somatropin recombinant: Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars.

Tolbutamide: Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.